首页> 外文期刊>Bone marrow transplantation >Rapamycin and T cell costimulatory blockade as post-transplant treatment promote fully MHC-mismatched allogeneic bone marrow engraftment under irradiation-free conditioning therapy.
【24h】

Rapamycin and T cell costimulatory blockade as post-transplant treatment promote fully MHC-mismatched allogeneic bone marrow engraftment under irradiation-free conditioning therapy.

机译:雷帕霉素和T细胞共刺激性阻断作为移植后治疗可在无辐射条件下促进完全MHC不匹配的同种异体骨髓植入。

获取原文
获取原文并翻译 | 示例
       

摘要

Hematopoietic macrochimerism, established by bone marrow transplantation, can be used as an approach for treating autoimmune disease and inducing transplant tolerance. In this study, we investigated whether a stable, high level of fully MHC-mismatched hematopoietic macrochimerism can be induced by using irradiation-free protocols, and whether rapamycin and T cell costimulatory blockades (anti-CD40L monoclonal antibody (mAb) and CTLA4Ig) as post-transplant treatment promote bone marrow engraftment. Donor-specific blood transfusion (DST), anti-lymphocyte serum (ALS), busulfan, and cyclophosphamide were given pretransplantation. Balb/c (H-2(d)) bone marrow cells, at a dose of 4 x 10(7), were infused into each C57BL/6 mouse (H-2(b)). Rapamycin, anti-CD40L mAb, and CTLA4Ig were then administered, either alone or in combination. Without ALS or busulfan and cyclophosphamide, macrochimerism can only rarely be induced. Donor-specific transfusion (DST) enhances induction of hematopoietic macrochimerism. Rapamycin, anti-CD40L mAb and CTLA4Ig, alone or in combination, induce a stable and high level of hematopoietic macrochimerism. In the chimeric mice, donor-derived cells were detected in all lymphohematopoietic tissues and donor-specific tolerance was induced in vitro. We conclude that a stable and high level of fully MHC-mismatched hematopoietic macrochimerism can be induced in mice after transplanting a single modest dose of bone marrow cells without irradiation. Rapamycin and T cell costimulatory blockade as post-transplant treatment promote bone marrow engraftment.
机译:通过骨髓移植建立的造血大嵌合体可以用作治疗自身免疫性疾病和诱导移植耐受的方法。在这项研究中,我们调查了使用无辐射方案是否可以诱导稳定,高水平的完全MHC不匹配的造血大嵌合体,以及雷帕霉素和T细胞共刺激性(抗CD40L单克隆抗体(mAb)和CTLA4Ig)移植后的治疗促进了骨髓的植入。在移植前先进行供体特异性输血(DST),抗淋巴细胞血清(ALS),白消安和环磷酰胺。将Balb / c(H-2(d))骨髓细胞以4 x 10(7)的剂量注入每只C57BL / 6小鼠(H-2(b))中。然后,雷帕霉素,抗CD40L mAb和CTLA4Ig单独或组合给药。如果没有ALS或白消安和环磷酰胺,大分子嵌合现象很少被诱导。供体特异性输血(DST)增强了造血大嵌合现象的诱导。雷帕霉素,抗CD40L mAb和CTLA4Ig单独或组合可诱导稳定且高水平的造血大嵌合体。在嵌合小鼠中,在所有淋巴造血组织中检测到供体来源的细胞,并在体外诱导了供体特异性耐受。我们得出的结论是,在不辐射的情况下移植单剂量的骨髓细胞后,可以在小鼠中诱导稳定和高水平的完全MHC不匹配的造血大嵌合体。雷帕霉素和T细胞共刺激性阻断作为移植后的治疗促进了骨髓的植入。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号